Skip to main content
Duality Biotherapeutics, Inc. logo

Duality Biotherapeutics, Inc. — Investor Relations & Filings

Ticker · 9606 LEI · 254900HZFACBOBP9HN21 HKEX Manufacturing
Open in API
Filings indexed 64 across all filing types
Latest filing 2026-02-23 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 9606

About Duality Biotherapeutics, Inc.

https://www.dualitybiologics.com/

Duality Biotherapeutics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of next-generation Antibody-Drug Conjugates (ADCs). The company focuses on creating innovative therapeutics for oncology and autoimmune diseases. Duality operates four proprietary ADC technology platforms—DITAC, DIBAC, DIMAC, and DUPAC—which form the foundation of its robust pipeline. This pipeline currently comprises 12 self-developed ADC candidates, including 7 clinical-stage assets, next-generation bispecific ADCs, and candidates specifically designed for autoimmune conditions. Duality aims to expand the therapeutic boundaries of ADCs through its advanced design insights and execution capabilities.

Recent filings

Filing Released Lang Actions
INSIDE INFORMATION STUDY RESULTS FROM CORE PRODUCT DB-1311/BNT324 AT ASCO GENITOURINARY CANCERS SYMPOSIUM 2026
Regulatory Filings Classification · 1% confidence The document is an official announcement from Duality Biotherapeutics, Inc. regarding clinical trial results for their product DB-1311/BNT324. It is formatted as a regulatory announcement (HKEX style) providing 'Inside Information' about study results to be presented at a medical symposium. Since it does not fit into specific categories like financial reports, dividends, or M&A, and serves as a general corporate disclosure of material information, it is classified as a Regulatory Filing (RNS).
2026-02-23 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' filed with the Hong Kong Stock Exchange. This is a standard regulatory filing required by the HKEX Listing Rules to report monthly movements in securities, including changes in issued shares, share options, and public float. It does not fit into specific categories like 'Annual Report' or 'Earnings Release' but is a mandatory regulatory disclosure regarding capital structure changes.
2026-02-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies to report monthly movements in securities, including share capital, share options, and other equity changes. Since it details changes in issued shares and capital structure, it falls under the category of share issues and capital changes.
2026-01-07 English
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 30, 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING' and provides a detailed breakdown of the votes cast for specific resolutions (1, 2, and 3) at an EGM held on December 30, 2025. It includes the number of votes for and against, the percentage of votes, and confirms the appointment of a scrutineer. This aligns perfectly with the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-12-30 English
2025 SHARE SCHEME
Regulatory Filings Classification · 1% confidence The document is a placeholder message from the Hong Kong Exchanges and Clearing Limited stating that the requested document has been removed by the issuer. Since it does not contain any substantive financial or corporate information and serves as a system-generated notice regarding a missing filing, it falls under the general regulatory announcement category.
2025-12-14 English
FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON DECEMBER 30, 2025
Proxy Solicitation & Information Statement Classification · 1% confidence The document is explicitly titled 'FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING'. It provides instructions and a template for shareholders to appoint a proxy to vote on their behalf at an upcoming meeting. This falls directly under the definition of Proxy Solicitation & Information Statement (PSI), as it is a material sent to shareholders to request votes for a meeting.
2025-12-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.